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Introduction
Cluster headache (CH) is characterised by short-lasting,
unilateral severe pain attacks, usually located in the
orbitotemporal region, accompanied by ipsilateral auto-
nomic phenomena and/or restlessness or agitation [1].
Untreated, the pain lasts 15 min to 3 h and can occur from
once every other day to 8 times a day. It is an excruciating
pain, driving some patients to thoughts of suicide.
In episodic CH (ECH), the attacks occur in cluster
periods lasting from one week to one year and are sepa-
rated by remission periods of at least one month (Table 1).
In chronic CH (CCH) the attacks occur almost every day
for more than one year without remission or with remis-
sions lasting less than one month. The chronic form can be
unremitting from onset, primary chronic cluster headache
(PCCH), or can evolve from the episodic form, secondary
chronic cluster headache (SCCH). The rarest variety is the
secondary episodic form (SECH), which begins as chron-
ic and becomes episodic.
In this review, we give an overview of demographics,
clinical manifestations, social habits, predictive factors,
head injury, genetics, neuroimaging and therapy of CCH.
In the separate sections, we will first compare ECH with
CCH, followed by a comparison of PCCH and SCCH.
Demographics
The exact prevalence of CH (and its subforms) is uncer-
tain. In some epidemiological surveys, the prevalence of
CH varies from 56 to 401 per 100 000 [2]. The highest
prevalence of 401 per 100 000 was found in a study in
which the diagnosis of CH was based on a review of
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4charts from patients who had been seen and diagnosed by
a wide variety of clinicians [3]. So, this high figure may
be biased.
The episodic form of CH is much more prevalent than
the chronic form. The exact ratio between chronic and
episodic CH, however, is unknown. Figures in the litera-
ture differ [4–6] (Table 2), probably because there is a dif-
ference in patient selection. Within the group of patients
with CCH, the prevalence of the subgroups (PCCH,
SCCH, SECH) is also not exactly known. In a follow-up
study of 109 CCH patients during at least 5 years, 64%
could be classified as PCCH and 36% as SCCH [7].
As to the course of CH, Pearce [8] conducted a follow-
up study of 101 patients with ECH and 7 patients with
CCH during 16 years. Four patients (3.96%) in the episod-
ic group changed to a chronic pattern, whereas in the
chronic group, 2 patients (28.6%) changed to an episodic
pattern. Another study followed 189 patients with CH
over a period longer than 10 years [9]. Almost 13% of
ECH patients became secondarily chronic and 32.6% of
CCH patients became secondarily episodic.
In 1956, Horton [10] reported a male-to-female ratio of
CH of 6.7:1 and this was used in clinical practice for years.
Recently, the male-to-female ratio was found to be much
lower, namely 2.5:1 [5]. This decrease in ratio might be
explained by the fact that specific male behavioural traits
are possible cluster triggers and that more women are tak-
ing over these traits. Also, more women are contributing to
household incomes and therefore seek treatment sooner.
Another explanation might be that in the past, many women
with CH were first diagnosed with migraine, because of
atypical features of the CH, such as longer duration of an
attack. A male to female ratio of 3.6:1 was found for ECH
and 4.2:1 for CCH [4]. Another study found a male to
female ratio of 3.2:1 in PCCH and 2.4:1 in SCCH [11].
Mean age at onset appeared to be later in CCH than in
ECH: 38 vs. 32 years [6]. Mean age at onset was later in
PCCH compared to SCCH: approximately 37 vs. 29 years
[11, 12].
In conclusion, the exact prevalence of CH and its sub-
forms is uncertain, but it is clear that episodic CH is much
more prevalent than chronic CH. There is a male prepon-
derance in CH, especially in the chronic form. In chronic
CH, the mean age at onset appeared to be about 6 years
later than in episodic CH. The mean age at onset is espe-
cially late in primary chronic CH.
Clinical manifestations
The diagnostic criteria for CH do not differentiate
between ECH and CCH in the clinical features of the
attacks. The distinction is only made in the occurrence and
duration of remission periods, but clinical studies also
found some differences in the characteristics of ECH and
CCH.
First, patients with CCH appear to have a mild, con-
tinuous headache between the attacks more often than
patients with ECH [6]. Second, a significant difference in
the site of pain appears to exist [5]. In both forms the site
of pain was predominantly retro-orbital and temporal, but
in CCH, more patients reported pain also in the upper
teeth, jaw, cheek, ear and shoulder. Besides, in CCH there
was more often a side change of the pain. Third, differ-
ences in autonomic features were found between ECH and
CCH. Lacrimation is the most often reported symptom in
both conditions, but rhinorrhoea occurred significantly
less in CCH. Osmophobia occurred more in CCH. Finally,
the reported attack duration between ECH and CCH was
shorter in the chronic group.
There are also some differences in characteristics
between PCCH and SCCH [11]. First, patients with PCCH
more often reported right-sided pain than patients with
Table 1 Diagnostic criteria for CH [1]
CH
A. At least 5 attacks fulfilling criteria B–D
B. Severe or very severe unilateral orbital, supraorbital and/or 
temporal pain lasting 15–180 min if untreated
C. Headache is accompanied by at least one of the following:
1. Ipsilateral conjunctival injection and/or lacrimation
2. Ipsilateral nasal congestion and/or rhinorrhoea
3. Ipsilateral eyelid oedema
4. Ipsilateral forehead and facial sweating
5. Ipsilateral miosis and/or ptosis
6. A sense of restlessness or agitation
D. Attacks have a frequency from one every other day to
8 per day
E. Not attributed to another disease
ECH
A. Attacks fulfilling criteria A–E for CH
B. At least two cluster periods lasting 7–365 days and
separated by pain-free remission periods of ≥1 month
CCH
A. Attacks fulfilling criteria A–E for CH
B. Attacks recur >1 year without remission periods or with 
remission periods lasting <1 month
Table 2 Episodic-to-chronic ratio
Study Number Episodic-to-
of patients chronic ratio
Manzoni (1997) [4] 482 7.5:1
Bahra et al. (2002) [5] 230 4:1
Van Vliet et al. (2003) [6] 1163 3.5:1
5SCCH, a finding that is not easily explained. Second, in
PCCH and SCCH, attack duration was most often between
15 and 120 min, but there was a statistically significant
larger proportion of patients with SCCH who reported
attacks lasting 120–180 min. Finally, patients with SCCH
were more likely to have their headache associated with
lacrimation, nasal congestion, rhinorrhoea and ptosis
while patients with PCCH more frequently reported facial
sweating and eyelid oedema.
In conclusion, there are some clinical differences
between episodic and chronic CH and also between the
two chronic forms.
Social habits
Some studies have looked at lifestyle habits in episodic vs.
chronic CH. Up to 90% of CH patients are smokers or for-
mer smokers [12] and there seem to be some differences
between the episodic and chronic forms (Tables 3 and 4).
In an Italian study, more male CCH patients smoked com-
pared to ECH patients and the chronic patients also
smoked more cigarettes a day [12]. Comparing the two
chronic forms, there were more and also more heavy
smokers in the SCCH group [11].
There were a few more alcohol drinkers in CCH com-
pared to ECH, but the chronic patients were evidently
heavier drinkers [12]. PCCH patients were more frequent-
ly heavy drinkers compared to SCCH patients [11].
A minor difference was found in the number of ECH
and CCH patients consuming coffee, but the chronic
patients drank more cups of coffee a day [12]. The per-
centage of regular coffee drinkers was the same in both
chronic conditions, however PCCH patients drank more
cups of coffee a day [11].
In conclusion, lifestyle habits such as smoking and the
consumption of alcohol or coffee are common habits in
CH, especially in chronic CH. Comparing the two chron-
ic conditions, smoking is a more common habit in SCCH
patients while consuming alcohol or coffee is more com-
mon among PCCH patients.
Secondary chronic cluster headache: predictive factors
Three factors were discovered that seemed to predict a
shift from ECH to CCH [9]. Firstly, the shift was associ-
ated with the duration of the disease. In 20.5% of episod-
ic patients with a course of CH longer than 20 years, there
was a shift towards the chronic form, versus a shift in
9.4% of patients with a shorter course than 20 years.
Secondly, a late age at onset appeared to predict a pattern
change. Mean age at onset was 27.1 years in ECH, while
the mean age at onset was 34.9 years in SCCH. Thirdly,
male sex was slightly related to a shift to a chronic condi-
tion: in SCCH, the percentage of females was 9.1% and
the percentage of males was 13.6%.
The characteristics of cluster and remission periods
were also found to be predictive factors in the shift from
ECH to SCCH (Table 5). More SCCH patients reported
cluster periods lasting more than 8 weeks before the CH
became chronic, compared to ECH patients who stayed
episodic [13]. Also, a larger proportion of SCCH patients
reported remission periods lasting less than 6 months.
More SCCH patients reported more than one cluster
period a year and more frequently reported sporadic
attacks.
Table 3 Social habits in ECH vs. CCH [12]
Social habit ECH, % CCH, %
Smoking habit
No. of patients 78.9 87.8
>20 cig/day 57.8 66.7
Alcohol intake
No. of patients 84.2 90.2
>100 g/day 19.2 29.7
Coffee intake
No. of patients 94.4 100
>6 cups/day 7.3 36.6
Table 4 Social habits in PCCH vs. SCCH [11]
Social habit PCCH, % SCCH, %
Smoking habit
No. of patients 65.8 87.1
>20 cig/day 21.1 48.4
Alcohol intake
No. of patients 76.3 64.5
50–100 g/day 27.6 15
Coffee intake
No. of patients 89.5 90.3
5–7 cups/day 57.9 32.3
Table 5 Characteristics of cluster and remission periods in ECH
and SCCH [13]
ECH, % SCCH, %
Cluster periods >8 weeks 8.5 25
Remission periods <6 months 6.6 28.6
More than 1 cluster/year 18.2 28.6
Sporadic attacks 5 25
6In conclusion, factors that were found to predict a shift
from episodic to chronic CH are: a longer course, a late
age at onset, male sex, longer cluster periods, shorter
remission periods, more cluster periods per year and more
frequent sporadic attacks.
Secondary episodic cluster headache: predictive factors
Four factors were found that favoured the evolution of
CCH into SECH [9]. The first one was the use of prophy-
lactic treatment (usually lithium). Of the chronic patients
who became secondary episodic, about 56% used prophy-
lactic medication. The second factor was an earlier
headache onset. CH onset was 26 years for SECH and
almost 35 years for PCCH. Thirdly, duration of the disease
longer than 20 years was positively related to the evolu-
tion from CCH to ECH. Only in 46.6% of patients with
CCH and a course longer than 20 years did the chronic
form persist. Fourthly, male sex appeared to relate posi-
tively to a shift from CCH to ECH: all of the patients in
the SECH group were men.
In conclusion, factors that were found to predict a shift
from chronic to episodic CH are: the use of prophylactic
treatment, an earlier age at onset, a longer course and
male sex.
Head injury
Head injury and CH have been frequently associated. In a
case-control study [14], significantly more CH patients
had a previous head trauma compared to the control group
(30.8% vs. 15.8%), and in another study, almost 37% of
CH individuals reported head injury vs. almost 17% of
age- and gender-matched migrainous controls [12].
Patients with CCH reported a head injury more often,
whether with or without loss of consciousness, compared
to patients with ECH (Table 6). Also, head injury occurred
more often on the same side as the headache in chronic
patients. Head injury preceded the onset of CH more often
in chronic patients [11] than episodic patients [13].
Individuals with PCCH reported head injury in their
history less frequently compared to SCCH [11], but in a
higher percentage of PCCH patients, the head injury pre-
ceded onset of CH. A significant difference was found in
the average number of years elapsing between head injury
and onset of CH when the analysis was restricted to head-
injured males with loss of consciousness. The average
latency period was 21.8 years for PCCH men and 5.5
years for SCCH men. Four of 28 SCCH patients had a sec-
ond head injury and in all these 4 patients, the second
head injury preceded the evolution from episodic to
chronic [13]. The mean latency period between the second
head injury and the evolution into SCCH was 11.0 years.
In conclusion, many CH patients report a head injury in
their medical history. The frequency of head injury is high-
er in chronic than episodic patients and also higher in
SCCH patients compared to PCCH patients. In most
chronic patients, the head injury preceded the onset of CH.
Genetics
It has been suggested that there is a genetic influence in
CH. CH has been described in monozygotic twins and also
in families in consecutive generations. In a French study
[15], a positive family history was found in 10.75% of CH
patients. Familial CH was found in 9.52% of ECH patients
and in 20% of CCH patients; the difference was not statis-
tically significant. Different forms of CH can occur within
the same family. Spierings et al. [16] described a family
with the occurrence of CH in three generations: an 8-year-
old boy with PCCH, his 42-year-old father with SCCH and
his 73-year-old paternal grandfather with ECH.
In conclusion, no difference in genetic factors seems to
exist between the episodic and chronic form. Different
forms of CH can occur in the same family.
Neuroimaging
PET studies in CH patients revealed that the ipsilateral
inferior posterior hypothalamus is activated during a CH
attack [17]. No difference was made between CCH and
ECH, because the ECH patients were used as controls
while they were not in a cluster period.
With voxel-based morphometry, a significant structur-
al difference in grey matter density bilateral in the inferi-
or posterior hypothalamus was found between CH patients
and healthy volunteers [18]. No comparison was made
between CCH and ECH patients.
In conclusion, the difference between ECH and CCH
in hypothalamic function and grey matter density has not
been studied yet.
Table 6 Head injury in CH [11–13]
Head injury ECH, % CCH, % PCCH, % SCCH, %
No. of patients 35.9 54.7 34.2 54.8
Pre-CH 45.3 70.0 76.9 64.7
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More patients with ECH than with CCH had success with
oxygen: 78.8% vs. 68.4% [19]. The greatest difference
was found when comparing ECH patients under 50 years
of age (92.9%) with CCH patients over 49 years of age
(57.1%). CH can also be treated with a hyperbaric form of
oxygen. In a placebo-controlled study, the treatment of
CCH patients with hyperbaric oxygen in 15 sessions every
other day for 4 weeks was more effective than placebo
[20]. The number of attacks and the analgesic consump-
tion declined in the group treated with hyperbaric oxygen,
while there was no change in the placebo group. However,
it is difficult to treat patients with this therapy, because it
requires hyperbaric chambers.
Patients with CCH responded well to the use of subcu-
taneous sumatriptan, but to a lesser extent than ECH
patients: 72.9% of ECH patients were pain free within 15
min compared to 60% of CCH patients [21]. Also, CCH
patients responded more slowly than patients with ECH.
In an open-label study [22], intranasal sumatriptan was
more effective in ECH than in CCH, but only 4 patients
with CCH and 6 with ECH participated. Within 30 min,
42% of headache attacks improved in ECH patients com-
pared to only 16% of headache attacks in CCH patients. In
a placebo-controlled study [23], no difference in efficacy of
sumatriptan nasal spray was found between episodic and
chronic patients. Unfortunately, no percentages were given.
Dihydroergotamine was more effective for ECH than
for CCH [24]: there was complete resolution in 73% of
ECH patients and in 46% of CCH patients.
Dihydroergotamine appeared to induce transformation
from CCH to ECH: of the 17 patients with CCH who
achieved complete success with dihydroergotamine, 3
experienced a transformation to ECH.
In a double-blind crossover study, significantly more
patients with ECH reported efficacy of oral zolmitriptan
than placebo (46.8% vs. 28.9%) [25]. In CCH however,
there was no significant difference.
In an open study with 48 patients [26], it was found
that ECH patients more often improved than CCH patients
on verapamil prophylaxis (73% vs. 60%), but this differ-
ence was not significant. Headache relief was obtained
after an average of 1.7 weeks in the episodic group and
after an average of 5 weeks in the chronic group. The
required average daily dose of verapamil was 354 mg in
ECH and 572 mg in CCH.
In an open study [27], 19 male CH patients (8 with
CCH and 11 with ECH) were treated with lithium. In all
chronic patients, there was at least a 75% improvement
within 2 weeks after starting the treatment. In the episod-
ic patients, there was an average improvement of only
15% with no improvement in 3 patients. Lithium was
compared with verapamil in a double-blind crossover trial
in CCH patients [28]. It appeared that both medications
were efficacious in preventing CCH, without significant
differences.
Methysergide appeared effective in approximately 65%
of ECH patients and in only 20% of CCH patients [29].
In an open-label study with 77 episodic and 15 chron-
ic patients, there was a marked relief with prednisone
therapy in 76.6% of patients with ECH and in 40% of
patients with CCH [29].
In an open-label study, topiramate rapidly induced
cluster remission in 64.3% of CCH patients and in 50% of
ECH patients [30]. All chronic patients and 75% of
episodic patients had poor or no response to other preven-
tive treatments.
Serum melatonin levels are reduced in CH patients
during a cluster period [31, 32]. In a double blind, place-
bo-controlled trial in 18 ECH and 2 PCCH patients, mela-
tonin appeared only effective in the prophylaxis of ECH
[33]. In another study, in 6 CCH patients and 3 ECH
patients who did not react to conventional therapy, there
was no effect of melatonin [34]. The lack of response in
CCH may reflect a fundamental difference between the
chronic and episodic condition.
In a placebo-controlled trial, capsaicin was superior to
placebo in reducing headache severity when delivered twice
a day in the ipsilateral nostril for seven days [35]. Episodic
patients appeared to benefit more than chronic patients.
In CCH cases resistant to medical management,
surgery could be a feasible option. Of 17 patients with
intractable CCH who underwent a partial or complete sec-
tion of the trigeminal nerve, 15 (88%) had complete or
near-complete relief of their CH in the immediate postop-
erative period [36]. Complete section produced better
results than partial section, but this difference was not sig-
nificant. Two patients had recurrence of the CH after ini-
tial complete relief.
In another study, 28 CCH patients underwent in total 39
microvascular decompression procedures of the trigeminal
nerve, alone or in combination with section and/or
microvascular decompression of the nervus intermedius
[37]. In 22 of 30 (73.3%) first time procedures, there was
a 50% relief or better. At follow-up, this success rate
dropped to 46.6%. Repeating the procedure was ineffec-
tive. Stimulation of the ipsilateral posterior hypothalamus
with stereotactic implants in five patients with medically
refractory CCH was successful [38]. All patients achieved
complete pain relief. The relief of pain occurred in two
patients after a couple of hours, in three patients in 1–4
weeks. Three patients remained pain free with prophylac-
tic medication, the other two patients stayed pain free with-
out medication. There were no adverse side effects of the
stimulation and there were no acute complications from
8the electrode implant procedure. Of course, these results
are from a limited number of patients. In a long-term fol-
low-up study of a patient with bilateral hypothalamic stim-
ulation, the stimulation appeared very successful, but there
were some adverse events, consisting of transient vertigo
and bradycardia [39]. Besides, the hypothalamus is impor-
tant for internal metabolic homeostasis and circadian
rhythms, so an extremely cautious patient selection for
hypothalamic stimulation is mandatory. Recently, propos-
als for patient selection are published [40].
In conclusion, symptomatic treatment with oxygen and
subcutaneous sumatriptan is more effective in ECH than
in CCH. Prophylactic medications are also more effective
in ECH than in CCH with the exception of topiramate and
especially lithium. Dihydroergotamine is more effective
in ECH, but appears to induce transformation from CCH
to ECH. Surgery could be a feasible option for CCH
patients resistant to medical management. Stimulation of
the posterior hypothalamus seemed to be very effective in
medically refractory CCH, but the results are from a very
limited number of patients.
Conclusions
CH is a severe headache disorder. Especially its chronic
forms are very disabling and difficult to treat. In approxi-
mately 4–13% of cases, the episodic condition can devel-
op to a chronic form of CH. It is remarkable that little is
known about factors that influence the evolution of ECH
to CCH. Such knowledge can, however, be of great value,
as it may lead to treatment or preventive measures to
avoid this evolution. In our present review of (mainly ret-
rospective) studies, three factors seemed to predict the
shift from ECH to CCH: a longer course of CH, a late age
at onset and male sex. The influence of male sex may have
been overestimated, as there were not many women exam-
ined in these studies. The role of a long duration of CH is
also not very strong, because the longer the duration of a
disease, the more time there is for a pattern change. The
characteristics of cluster and remission periods also
seemed to predict a shift from ECH to CCH.
When comparing ECH with CCH, there did not appear
to be many clinical differences. The main difference we
found was the effect of prophylactic medication, which is
larger in ECH than in CCH, with the exception of topira-
mate and lithium. Selection bias is a likely cause for these
findings. It is striking that dihydroergotamine, although
more effective in ECH, appears to induce transformation
from CCH to ECH.
The comparison of PCCH with SCCH revealed a male
preponderance in PCCH, but not many clinical differences.
Not much is known about the pathophysiology of CH.
Even less is known about the chronic forms of CH.
Patients with CCH more often report a head injury and
some studies point to differences in social habits between
ECH and CCH. These social habits are more often dis-
played by chronic patients. But are these habits secondary
phenomena to the suffering of chronic CH, or do they play
a role in the onset? Also, are there more factors that could
favour the development of chronic CH, besides a head
injury and lifestyle habits? For instance, does the frequent
use of triptans play a role? Further research, for example
by means of prospective and longitudinal studies, might
lead to more insight in the pathophysiology of CCH.
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